Studies how genes affect response to semaglutide in people with obesity or diabetes
Tests semaglutide in adults with obesity or type 2 diabetes, looking at genetic differences.
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Lancaster, United StatesSee the site
- Trial code
- Registry title
- Pharmacogenetics of Response to GLP1R Agonists
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 600 people, planned
- Started
- 11 Apr 2022
- Expected to end
- Apr 2028
- Type of study
- Interventional
- Treatments tested
- Semaglutide Pen Injector [Ozempic]
- Record updated
- 27 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults of Amish descent with a BMI of 27 kg/m2 or more. They take semaglutide for six weeks so researchers can study how genes affect the response.
- Age
- 18 Years to 89 Years
- Sex
- All sexes can join.
- Disease stage
- BMI of 27 kg/m2 or more (overweight or obese). People with a history of diabetes cannot join.
- Earlier treatment
- People must be able to stop any drug, vitamin or supplement that might change the response to semaglutide.
Main reasons for not taking part
- History of diabetes (HbA1c > 6.5% (48 mmol/mol) or random glucose >200 mg/dL (11.1 mmol/L))
- Sexually active woman of childbearing age
- Known allergy to semaglutide
- Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2
- eGFR < 60 mL/min/1.73 sq. m., or AST or ALT more than 2X the upper limit of normal
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- BMI greater than or equal to 27 kg/m2
- Of Amish Descent
Who cannot take part
- Unable to discontinue a drug, vitamin, or nutritional supplement, which in the judgment of the research physician or PIs might alter the response to semaglutide
- Known allergy to semaglutide
- Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2
- History of diabetes (HbA1c > 6.5% or random glucose >200 mg/dL)
- eGFR < 60 mL/min/1.73 sq. m
- AST or ALT in excess of 2X the upper limit of normal
- Woman of childbearing age who is sexually active
- Medical issues, which in the judgment of the research physician or PIs might increase the risk associated with participation in the study
- Hematocrit < 35%
- TSH < 0.4 o4 > 5.5
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 89 years old?
Where in United States
- Amish Research ClinicLancaster, United StatesContact: Susan Shaub, RNTaking people
About the trial
What the trial wants to find out
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims:
Read full original descriptionShow less
1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated first phase insulin secretion in the two FSIGTs (before and after administration of drug). 2. Specific Aim #2. To identify genetic variants associated with the effect of a GLP1R agonist to accelerate the rate of glucose disappearance as assessed in the two FSIGTs (before and after administration of drug).
Genotyping will be conducted using a high-density array with comprehensive coverage of DNA sequence variants. In addition, the analysis will leverage a global imputation panel generated from 1,025 Amish individuals.
The group in the trial
- Open label administration of semaglutideTreatment being tested
Semaglutide: 0.25 mg, sc, q.week for 4 weeks followed by 0.5 mg, sc, q.week for 2 weeks
Treatment: Semaglutide Pen Injector [Ozempic]
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Pharmacogenetics of Response to GLP1R Agonists
- Plain-language title
- Studies how genes affect response to semaglutide in people with obesity or diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05071898, who can take part
- Record updated
- 27 July 2026